Details about Mark Sculpher

Homepage:

https://www.york.ac.uk/che/staff/research/mark-sculpher/

Access statistics for papers by Mark Sculpher.

Last updated 2025-05-29. Update your information in the RePEc Author Service.

Short-id: psc810

---

Jump to Journal Articles Books Edited books Chapters

Working Papers

2021

1. Comparing smoking cessation to screening and brief intervention for alcohol in distributional cost effectiveness analysis to explore the sensitivity of results to socioeconomic inequalities characterised in model inputs
   Working Papers, Centre for Health Economics, University of York

2019

2. Economic analysis for health benefits package design
   Working Papers, Centre for Health Economics, University of York
3. Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision-makers
   LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library View citations (18)
   See also Journal Article Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers, Applied Health Economics and Health Policy, Springer (2019) View citations (24) (2019)

2017

4. Scoping review on social care economic evaluation methods
   Working Papers, Centre for Health Economics, University of York

2016

5. Supporting the development of an essential health package: principles and initial assessment for Malawi
   Working Papers, Centre for Health Economics, University of York View citations (3)
6. Using electronic health records to predict costs and outcomes in stable coronary artery disease
   LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library View citations (6)

2015

7. Country-level cost-effectiveness thresholds: initial estimates and the need for further research
   Working Papers, Centre for Health Economics, University of York View citations (44)

2014

8. Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?
   Working Papers, Centre for Health Economics, University of York View citations (10)

2013

9. Methods for the estimation of the NICE cost effectiveness threshold
   Working Papers, Centre for Health Economics, University of York View citations (49)

2012

10. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions
    Working Papers, Centre for Health Economics, University of York View citations (25)

2011

11. Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS
    Working Papers, Centre for Health Economics, University of York View citations (12)

2010

12. Appropriate Perspectives for Health Care Decisions
    Working Papers, Centre for Health Economics, University of York View citations (50)

2009

13. MRC-NICE scoping project: identifying the national institute for health and clinical excellence’s methodological research priorities and an initial set of priorities
    Working Papers, Centre for Health Economics, University of York View citations (2)

2007

14. Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions
    Working Papers, Centre for Health Economics, University of York View citations (15)

2006

15. Defining and characterising structural uncertainty in decision analytic models
    Working Papers, Centre for Health Economics, University of York View citations (7)

2005

16. The value of implementation and the value of information: combined and uneven development
    Working Papers, Centre for Health Economics, University of York View citations (3)
    See also Journal Article The Value of Implementation and the Value of Information: Combined and Uneven Development, Medical Decision Making (2008) View citations (18) (2008)

2000

17. Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling
    Working Papers, Centre for Health Economics, University of York View citations (11)

1999

18. A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis
    Working Papers, Centre for Health Economics, University of York View citations (1)
19. Building Uncertainty into Cost-Effectiveness Rankings: Portfolio Risk-Return Trade-Offs and Implications for Decision Rules
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada
20. Income Effects of Reduced Health and Health Effects of Reduced Income: Implications for Health State Valuation
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada
21. Recognizing Preference Diversity: The Use of Preference Sub-Groups in Cost-Effectiveness Analysis
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada

1996

22. Antenatal testing for HIV Infection: Developing a Model for Economic Evaluation
    Discussion Papers, Brunel University, Health Economics Research Group

1995

23. Economic Evaluation in Health Care Research and Development: Undertake it Early and Often
    Discussion Papers, Brunel University, Health Economics Research Group View citations (2)

Journal Articles

2025

1. A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
   PharmacoEconomics, 2025, 43, (4), 363-373
2. Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England
   Applied Health Economics and Health Policy, 2025, 23, (1), 5-17
3. Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in Nepal
   PLOS ONE, 2025, 20, (2), 1-12

2024

4. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required
   Health Economics, 2024, 33, (4), 804-819
5. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment
   Health Economics, Policy and Law, 2024, 19, (2), 153-173

2023

6. Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
   PharmacoEconomics, 2023, 41, (10), 1165-1174 View citations (1)

2022

7. Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol
   PharmacoEconomics, 2022, 40, (3), 309-321 View citations (1)
8. Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates
   PLOS Neglected Tropical Diseases, 2022, 16, (6), 1-17
9. Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making
   Medical Decision Making, 2022, 42, (1), 17-27

2021

10. Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.†by Sampson, Firth, and Towse
    Medical Decision Making, 2021, 41, (3), 258-260 View citations (3)
11. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems
    Health Economics, 2021, 30, (11), 2649-2666 View citations (1)
12. Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
    PharmacoEconomics, 2021, 39, (8), 879-887 View citations (2)

2020

13. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    PharmacoEconomics, 2020, 38, (3), 247-257 View citations (1)
14. Distributional cost effectiveness analysis of West Yorkshire low emission zone policies
    Health Economics, 2020, 29, (5), 567-579
15. Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts
    Medical Decision Making, 2020, 40, (4), 448-459 View citations (4)

2019

16. Adherence to the iDSI reference case among published cost-per-DALY averted studies
    PLOS ONE, 2019, 14, (5), 1-13 View citations (2)
17. Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers
    Applied Health Economics and Health Policy, 2019, 17, (5), 577-590 View citations (24)
    See also Working Paper Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision-makers, LSE Research Online Documents on Economics (2019) View citations (18) (2019)

2018

18. Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment
    Medical Decision Making, 2018, 38, (4), 495-508 View citations (1)
19. Future Directions for Cost-effectiveness Analyses in Health and Medicine
    Medical Decision Making, 2018, 38, (7), 767-777 View citations (2)
20. How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework
    Health Economics, 2018, 27, (2), e41-e54 View citations (2)
21. Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care
    PLOS ONE, 2018, 13, (1), 1-13 View citations (2)
22. Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system
    Health Economics, 2018, 27, (2), e28-e40 View citations (1)

2017

23. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs
    Health Economics, 2017, 26, (S1), 109-123 View citations (10)
24. Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee
    PLOS ONE, 2017, 12, (3), 1-18
25. How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants
    Medical Decision Making, 2017, 37, (2), 148-161 View citations (4)

2016

26. Should the Lambda (λ) Remain Silent?
    PharmacoEconomics, 2016, 34, (4), 323-329

2015

27. CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
    Health Economics, 2015, 24, (1), 1-7 View citations (25)

2014

28. Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial
    PLOS ONE, 2014, 9, (11), 1-12
29. The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis
    Medical Decision Making, 2014, 34, (8), 951-964 View citations (2)
30. What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer
    Applied Health Economics and Health Policy, 2014, 12, (5), 497-510

2013

31. Acknowledging Patient Heterogeneity in Economic Evaluation
    PharmacoEconomics, 2013, 31, (2), 111-123 View citations (3)
32. Methods Development for Health Technology Assessment
    Medical Decision Making, 2013, 33, (3), 313-315

2012

33. Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV
    Medical Decision Making, 2012, 32, (1), 70-82
34. Golimumab for the Treatment of Psoriatic Arthritis
    PharmacoEconomics, 2012, 30, (4), 257-270 View citations (23)
35. Model Parameter Estimation and Uncertainty Analysis
    Medical Decision Making, 2012, 32, (5), 722-732 View citations (32)
36. Real Economics Needs to Reflect Real Decisions
    PharmacoEconomics, 2012, 30, (2), 133-136 View citations (3)

2011

37. Catalogue of EQ-5D Scores for the United Kingdom
    Medical Decision Making, 2011, 31, (6), 800-804 View citations (8)
38. Dangerous omissions: the consequences of ignoring decision uncertainty
    Health Economics, 2011, 20, (2), 212-224 View citations (14)

2010

39. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?
    The European Journal of Health Economics, 2010, 11, (1), 57-66
40. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods
    Health Economics, 2010, 19, (10), 1132-1136 View citations (3)

2009

41. Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations
    Health Policy, 2009, 93, (2-3), 85-92 View citations (30)

2008

42. Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration
    Medical Decision Making, 2008, 28, (1), 33-43 View citations (2)
43. The Value of Implementation and the Value of Information: Combined and Uneven Development
    Medical Decision Making, 2008, 28, (1), 21-32 View citations (18)
    See also Working Paper The value of implementation and the value of information: combined and uneven development, Working Papers (2005) View citations (3) (2005)

2007

44. A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
    PharmacoEconomics, 2007, 25, (10), 829-841
45. Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling
    Medical Decision Making, 2007, 27, (4), 471-490 View citations (6)
46. Efficiency, Equity, and Budgetary Policies
    Medical Decision Making, 2007, 27, (2), 128-137 View citations (15)
47. Recombinant Erythropoietin for Chemotherapy-Related Anaemia
    PharmacoEconomics, 2007, 25, (3), 223-237 View citations (3)

2006

48. An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery
    Medical Decision Making, 2006, 26, (5), 480-496 View citations (7)
49. Assessing Generalisability in Model-Based Economic Evaluation Studies
    PharmacoEconomics, 2006, 24, (12), 1181-1197 View citations (3)
50. Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion
    Health Economics, 2006, 15, (1), 1-4 View citations (20)
51. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis
    Health Economics, 2006, 15, (4), 373-381 View citations (13)
52. Whither trial‐based economic evaluation for health care decision making?
    Health Economics, 2006, 15, (7), 677-687 View citations (44)

2005

53. Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models
    Health Economics, 2005, 14, (5), 471-485 View citations (22)
54. Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model
    Medical Decision Making, 2005, 25, (5), 493-510 View citations (6)
55. Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response
    Medical Decision Making, 2005, 25, (5), 511-519 View citations (8)
56. Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility
    Health Economics, 2005, 14, (5), 487-496 View citations (31)
57. Estimating utility data from clinical indicators for patients with stable angina
    The European Journal of Health Economics, 2005, 6, (4), 347-353 View citations (7)
58. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
    Health Economics, 2005, 14, (4), 339-347 View citations (76)

2004

59. Unfinished Symphony: A Tribute to the Life and Career of Bernie O’Brien (1959–2004)
    Medical Decision Making, 2004, 24, (5), 538-544

2002

60. Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply
    Health Economics, 2002, 11, (7), 653-654
61. Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions
    Social Science & Medicine, 2002, 54, (9), 1369-1377 View citations (5)

2001

62. Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis
    Health Economics, 2001, 10, (4), 317-324 View citations (15)
63. Representing uncertainty: the role of cost‐effectiveness acceptability curves
    Health Economics, 2001, 10, (8), 779-787 View citations (82)

2000

64. Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy
    PharmacoEconomics, 2000, 17, (4), 361-370 View citations (1)
65. Income Effects of Reduced Health and Health Effects of Reduced Income
    Medical Decision Making, 2000, 20, (2), 207-215 View citations (2)

1998

66. The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia
    Health Economics, 1998, 7, (2), 129-142 View citations (2)

1995

67. Sensitivity analysis in economic evaluation: A review of published studies
    Health Economics, 1995, 4, (5), 355-371 View citations (13)

Books

2006

1. Decision Modelling for Health Economic Evaluation
   OUP Catalogue, Oxford University Press View citations (414)

Edited books

2020

1. Global Health Economics:Shaping Health Policy in Low- and Middle-Income Countries
   World Scientific Books, World Scientific Publishing Co. Pte. Ltd. View citations (1)

Chapters

2020

1. Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement
   Chapter 3 in Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, 2020, pp 75-97 View citations (3)
2. Supporting the Development of Health Benefits Packages (HBPs): Principles and Initial Assessment for Malawi
   Chapter 10 in Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, 2020, pp 265-273

2012

3. Decision-making with Uncertainty: The Value of Information
   Chapter 51 in The Elgar Companion to Health Economics, Second Edition, 2012
   Also in Chapter 48 in The Elgar Companion to Health Economics, 2006 (2006)